Cargando…

Development of a CHO cell line for stable production of recombinant antibodies against human MMP9

BACKGROUND: Human matrix metalloproteinase 9 (hMMP9) is a biomarker in several diseases, including cancer, and the need for developing detectors and inhibitors of hMMP9 is increasing. As an antibody against hMMP9 can be selectively bound to hMMP9, the use of anti-MMP9 antibody presents new possibili...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Jina, Kim, Eun-Jung, Kim, Joo-Kyung, Park, Tai Hyun, Kim, Byung-Gee, Jeong, Hee-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903741/
https://www.ncbi.nlm.nih.gov/pubmed/35255869
http://dx.doi.org/10.1186/s12896-022-00738-6
_version_ 1784664836653711360
author Ryu, Jina
Kim, Eun-Jung
Kim, Joo-Kyung
Park, Tai Hyun
Kim, Byung-Gee
Jeong, Hee-Jin
author_facet Ryu, Jina
Kim, Eun-Jung
Kim, Joo-Kyung
Park, Tai Hyun
Kim, Byung-Gee
Jeong, Hee-Jin
author_sort Ryu, Jina
collection PubMed
description BACKGROUND: Human matrix metalloproteinase 9 (hMMP9) is a biomarker in several diseases, including cancer, and the need for developing detectors and inhibitors of hMMP9 is increasing. As an antibody against hMMP9 can be selectively bound to hMMP9, the use of anti-MMP9 antibody presents new possibilities to address hMMP9-related diseases. In this study, we aimed to establish a stable Chinese hamster ovary (CHO) cell line for the stable production of antibodies against hMMP9. RESULTS: Weconstructed recombinant anti-hMMP9 antibody fragment-expressing genes and transfected these to CHO cells. We chose a single clone, and successfully produced a full-sized antibody against hMMP9 with high purity, sensitivity, and reproducibility. Subsequently, we confirmed the antigen-binding efficiency of the antibody. CONCLUSIONS: We developed a novel recombinant anti-hMMP9 antibody via a CHO cell-based mammalian expression system, which has a high potential to be used in a broad range of medical and industrial areas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12896-022-00738-6.
format Online
Article
Text
id pubmed-8903741
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89037412022-03-18 Development of a CHO cell line for stable production of recombinant antibodies against human MMP9 Ryu, Jina Kim, Eun-Jung Kim, Joo-Kyung Park, Tai Hyun Kim, Byung-Gee Jeong, Hee-Jin BMC Biotechnol Research BACKGROUND: Human matrix metalloproteinase 9 (hMMP9) is a biomarker in several diseases, including cancer, and the need for developing detectors and inhibitors of hMMP9 is increasing. As an antibody against hMMP9 can be selectively bound to hMMP9, the use of anti-MMP9 antibody presents new possibilities to address hMMP9-related diseases. In this study, we aimed to establish a stable Chinese hamster ovary (CHO) cell line for the stable production of antibodies against hMMP9. RESULTS: Weconstructed recombinant anti-hMMP9 antibody fragment-expressing genes and transfected these to CHO cells. We chose a single clone, and successfully produced a full-sized antibody against hMMP9 with high purity, sensitivity, and reproducibility. Subsequently, we confirmed the antigen-binding efficiency of the antibody. CONCLUSIONS: We developed a novel recombinant anti-hMMP9 antibody via a CHO cell-based mammalian expression system, which has a high potential to be used in a broad range of medical and industrial areas. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12896-022-00738-6. BioMed Central 2022-03-07 /pmc/articles/PMC8903741/ /pubmed/35255869 http://dx.doi.org/10.1186/s12896-022-00738-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ryu, Jina
Kim, Eun-Jung
Kim, Joo-Kyung
Park, Tai Hyun
Kim, Byung-Gee
Jeong, Hee-Jin
Development of a CHO cell line for stable production of recombinant antibodies against human MMP9
title Development of a CHO cell line for stable production of recombinant antibodies against human MMP9
title_full Development of a CHO cell line for stable production of recombinant antibodies against human MMP9
title_fullStr Development of a CHO cell line for stable production of recombinant antibodies against human MMP9
title_full_unstemmed Development of a CHO cell line for stable production of recombinant antibodies against human MMP9
title_short Development of a CHO cell line for stable production of recombinant antibodies against human MMP9
title_sort development of a cho cell line for stable production of recombinant antibodies against human mmp9
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903741/
https://www.ncbi.nlm.nih.gov/pubmed/35255869
http://dx.doi.org/10.1186/s12896-022-00738-6
work_keys_str_mv AT ryujina developmentofachocelllineforstableproductionofrecombinantantibodiesagainsthumanmmp9
AT kimeunjung developmentofachocelllineforstableproductionofrecombinantantibodiesagainsthumanmmp9
AT kimjookyung developmentofachocelllineforstableproductionofrecombinantantibodiesagainsthumanmmp9
AT parktaihyun developmentofachocelllineforstableproductionofrecombinantantibodiesagainsthumanmmp9
AT kimbyunggee developmentofachocelllineforstableproductionofrecombinantantibodiesagainsthumanmmp9
AT jeongheejin developmentofachocelllineforstableproductionofrecombinantantibodiesagainsthumanmmp9